Intuitive Venture Partners | Venture Capital Firms NYC | Investment Bank New York City
Transactions News Contact Login
The FIRM Testimonials
Managing Partners Business Relationships
Investment Banking Services Proprietary Investment Opportunities
About The FIRM Testimonials Team Managing Partners Business Relationships Services Investment Banking Services Proprietary Investment Opportunities TransactionsNewsContactLogin
Intuitive Venture Partners | Venture Capital Firms NYC | Investment Bank New York City

Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research

Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in

Intuitive Venture PartnersApril 8, 20242024, entera bio
Facebook0 Twitter LinkedIn0 Reddit Tumblr 0 Likes
Previous

Serve Robotics Inc. Announces Pricing of $40 Million Public Offering and Uplisting to the Nasdaq Capital Market Under New Ticker "SERV"

Intuitive Venture PartnersApril 17, 20242024, Serve Robotics
Next

Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint

Intuitive Venture PartnersMarch 26, 20242024, entera bio

Intuitive Venture Partners, LLC. • 777 Westchester Ave, Suite 101 • White Plains, NY 10604

Intuitive Venture Partners
777 Westchester Avenue,
White Plains, NY, 10604,
United States
212-612-3221 info@intuitivevp.com
Hours
Mon 8am - 5pm
Tue 8am - 5pm
Wed 8am - 5pm
Thu 8am - 5pm
Fri 8am - 5pm
 

2023 INTUITIVE VENTURE PARTNERS, LLC. ALL RIGHTS RESERVED. SECURITIES OFFERED THROUGH
NETWORK 1 FINANCIAL SECURITIES, INC., A REGISTERED BROKER-DEALER, MEMBER FINRA AND SIPC

broker-check-sml.png
Terms of UseContact